Clopidogrel
Small molecule targets CYP2C8, P2RY12 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | PLAVIX | — | 2002-02-27 – 2011-05-06 | fda.gov ↗ |
| Approved | EU (EMA) | Iscover | — | 1998-07-14 | europa.eu ↗ |
| Approved | US (FDA) | PLAVIX | — | 1997-11-17 | fda.gov ↗ |
Trials 325 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT06933056 | Sep 2025 → Sep 2026 expected | — | University of Michigan | Recruiting | No outcome recorded |
| Phase 0 | NCT06692933 | Jun 2024 → Aug 2027 expected | — | Washington State University | Recruiting | No outcome recorded |
| Phase 0 | NCT06339021 | Apr 2024 → Dec 2026 expected | ST-elevation myocardial infarction | Shenyang Northern Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT04822363 | Aug 2021 → May 2025 | — | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 148 trials | ||||||
| Phase 1 | NCT07265466 | Nov 2025 → Mar 2026 overdue | — | Onconic Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07040787 | Jul → Aug 2025 | glomerulonephritis, hemolytic anemia | Chengdu Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06584812 | Sep → Dec 2024 | acute coronary syndrome, ischemic stroke | Tianjin Institute of Pharmaceutical Research Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06164834 | Dec 2023 → Nov 2024 | — | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT05574374 | Sep 2022 → Mar 2023 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT05162053 | Dec 2021 → Nov 2022 | acute coronary syndrome | Jiangsu vcare pharmaceutical technology co., LTD | Completed | No outcome recorded |
| Phase 1 | NCT04809818 | Mar → Aug 2021 | ischemic stroke | Lumosa Therapeutics Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04305587 | Mar 2020 → Jul 2021 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04171687 | Oct 2019 → Feb 2020 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03814642 | Jan → Jul 2019 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03698513 | Oct 2018 → Feb 2019 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03245489 | Mar 2018 → Nov 2023 | head and neck cancer | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1 | NCT03496506 | Mar → May 2018 | — | Actelion | Completed | No outcome recorded |
| Phase 1 | NCT03430661 | Jan 2018 → May 2019 | — | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03392051 | Dec 2017 → Mar 2018 | cardiovascular disorder, hyperlipoproteinemia | Akcea Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03471169 | Apr 2017 → Dec 2018 | cerebrovascular disorder | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
| Phase 1 | NCT02922465 | Sep → Oct 2016 | — | Kowa Research Institute, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02560688 | Dec 2015 → Mar 2016 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT02554721 | Aug 2015 → Mar 2018 | — | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03054207 | Jun 2015 → Apr 2017 | HIV infectious disease | Jules Desmeules | Terminated | No outcome recorded |
| Phase 1 | NCT02010632 | Aug 2013 → Oct 2014 | — | Khon Kaen University | Completed | No outcome recorded |
| Phase 1 | NCT01768637 | Jan 2013 → Apr 2014 | chronic kidney disease | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01469416 | Mar 2012 → May 2013 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT01263093 | Dec 2010 → Mar 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01210339 | Nov 2010 → Aug 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01557335 | Nov 2010 → Feb 2011 | platelet aggregation, spontaneous | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT01108588 | Jun → Aug 2010 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01147588 | May 2010 → May 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00942175 | Dec 2009 → Jun 2010 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT00989300 | Nov 2009 → Mar 2010 | — | Janssen Cilag S.A.S. | Completed | No outcome recorded |
| Phase 1 | NCT01129427 | Aug → Nov 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01129414 | Jun → Aug 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01123824 | Apr → Aug 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01409616 | Apr → Sep 2009 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT01129271 | Apr → Jun 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01129388 | Mar → May 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01129063 | Mar → May 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02171598 | Feb → Jul 2009 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01129375 | Feb → May 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01447563 | May → Jun 2008 | — | Hospital Universitario Dr. Jose E. Gonzalez | Terminated | No outcome recorded |
| Phase 1 | NCT01603342 | Dec 2007 → Jan 2008 | vascular hemostatic disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00696566 | Nov 2007 → Mar 2008 | coronary artery disorder | Sheffield Teaching Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 1 | NCT00413608 | Jan 2007 → Jan 2009 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 1 | NCT00363753 | Aug 2006 → Mar 2007 | aspirin resistance, transient ischemic attack | University of California, San Diego | Withdrawn | No outcome recorded |
| Phase 1 | NCT00648947 | Dec 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT02262650 | Apr → May 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02222987 | Feb → Mar 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02265289 | Jan → Feb 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04168398 | Jul 2019 → Nov 2021 | limb ischemia | Mansoura University | Completed | No outcome recorded |
| Phase 1/2 | NCT02320357 | Aug 2015 → Sep 2017 | systemic lupus erythematosus | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 224 trials | ||||||
| Phase 2 | NCT07384702 | Jun 2026 → Jun 2030 expected | staphylococcus aureus infection | Andalusian Public Foundation for Health Research in Seville | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06638151 | Sep 2025 → Jul 2026 | ischemic stroke | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT05567562 | Mar 2024 → Feb 2025 | pulmonary emphysema | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05926271 | Jul 2023 → Jun 2026 overdue | acute coronary syndrome | St. Antonius Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05514938 | Nov 2022 → May 2025 | acute coronary syndrome, coronary artery disorder, lip disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT05546320 | Oct 2022 → Mar 2025 | migraine disorder, patent foramen ovale | Chinese Academy of Medical Sciences, Fuwai Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04824911 | Mar 2021 → Feb 2025 | stroke disorder | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03606642 | Nov 2018 → Dec 2021 | atherosclerosis, coronary artery disorder | HonorHealth Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT02565693 | Sep 2014 → Jan 2021 | atrial fibrillation, intracerebral hemorrhage | UMC Utrecht | Completed | No outcome recorded |
| Phase 2 | NCT01979445 | Dec 2013 → Jan 2014 | coronary artery disorder | The Medicines Company | Completed | No outcome recorded |
| Phase 2 | NCT01955512 | May 2013 → May 2014 | asthma | University of Southampton | Completed | No outcome recorded |
| Phase 2 | NCT02285751 | Nov 2012 → Jul 2020 | critical illness polyneuropathy | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 2 | NCT01738100 | Sep 2012 → Dec 2016 | ST-elevation myocardial infarction | Hyeon-Cheol Gwon | Unknown | No outcome recorded |
| Phase 2 | NCT01960296 | Jan 2012 → May 2013 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT01115738 | May 2010 → Nov 2011 | acute coronary syndrome | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00940784 | Jun 2009 → Jan 2011 | acquired polycythemia vera | Ronald Hoffman | Withdrawn | No outcome recorded |
| Phase 2 | NCT01103440 | Apr 2007 → Jun 2009 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT00357968 | Aug 2006 → Jun 2007 | coronary artery disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00356135 | Jul 2006 → Dec 2008 | acute coronary syndrome, arteriosclerosis disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00263211 | Jan 2006 → Sep 2009 | breast cancer | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT00360386 | Mar 2004 → Feb 2005 | ischemic disease | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00115375 | Jan 2004 → Apr 2006 | blood platelet disease, congenital heart defects, multiple types | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00406991 | Jun 2003 → Mar 2006 | diabetes mellitus, diabetic retinopathy | Schepens Eye Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00105209 | Apr 2002 → Dec 2003 | pulmonary arterial hypertension | Kawut, Steven, MD | Completed | No outcome recorded |
| Phase 2/39 trials | ||||||
| Phase 2/3 | NCT05657041 | Apr 2023 → Aug 2024 | coronary artery disorder | St. Antonius Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT05098704 | Jun 2022 → Jun 2032 expected | systemic sclerosis | University Hospital, Bordeaux | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05122455 | Sep 2021 → Jun 2024 | — | University of Sao Paulo | Completed | No outcome recorded |
| Phase 2/3 | NCT04491695 | Sep 2020 → Dec 2022 | stroke disorder | Capital Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02048228 | Oct 2014 → Mar 2016 | — | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02044146 | Sep 2014 → Oct 2016 | acute coronary syndrome | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 2/3 | NCT01894789 | Mar 2013 → Mar 2015 | coronary artery disorder | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 2/3 | NCT01184300 | Aug 2010 → Jul 2011 | acute coronary syndrome, coronary artery disorder | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 2/3 | NCT00109382 | May 2003 → Feb 2007 | transient ischemic attack | University of Calgary | Completed | No outcome recorded |
| Phase 354 trials | ||||||
| Phase 3 | NCT07512960 | Jun 2026 → May 2030 expected | — | Fondation Hôpital Saint-Joseph | Recruiting | No outcome recorded |
| Phase 3 | NCT07012629 | Nov 2025 → Sep 2031 expected | MRI defined brain infarct | Aarhus University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06853535 | May 2025 → Jun 2027 expected | ischemic stroke | Sichuan Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06165068 | Dec 2023 → Dec 2025 overdue | dry age related macular degeneration | Navamindradhiraj University | Recruiting | No outcome recorded |
| Phase 3 | NCT05952206 | Oct 2023 → Jan 2027 expected | coronary artery disorder | iVascular S.L.U. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06021990 | Oct 2023 → Sep 2024 | chronic obstructive pulmonary disease | Lady Reading Hospital, Pakistan | Unknown | No outcome recorded |
| Phase 3 | NCT05387954 | Jul 2023 → Jul 2031 expected | ischemic stroke, patent foramen ovale | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT05903976 | Jun 2023 → Jun 2025 | acute coronary syndrome, coronary artery disorder | Azienda Ospedaliera Universitaria Policlinico "G. Martino" | Unknown | No outcome recorded |
| Phase 3 | NCT02433587 | Oct 2019 → Jul 2021 | peripheral arterial disease | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded |
| Phase 3 | NCT03357874 | Oct 2018 → Jan 2023 | acute coronary syndrome | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 3 | NCT03635749 | Sep 2018 → Jan 2023 | transient ischemic attack | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03001960 | Mar 2017 → Mar 2018 | aortic valve stenosis, intracranial embolism | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 3 | NCT02966119 | Dec 2016 → Dec 2019 | intracerebral hemorrhage | University Hospital, Lille | Terminated | No outcome recorded |
| Phase 3 | NCT02869009 | Nov 2016 → Oct 2022 | ischemic stroke | General Hospital of Shenyang Military Region | Completed | No outcome recorded |
| Phase 3 | NCT02944123 | Sep 2016 → Feb 2020 | acute coronary syndrome | Dong-A University | Completed | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | No outcome recorded |
| Phase 3 | NCT02404363 | Jan 2016 → Dec 2017 | pancreatic adenocarcinoma | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 3 | NCT02798913 | Jan 2016 → Jun 2020 | peripheral arterial disease | Federico II University | Unknown | No outcome recorded |
| Phase 3 | NCT02217501 | Nov 2015 → Jan 2020 | peripheral arterial disease | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01763320 | Mar 2014 → Nov 2016 | ischemic stroke | Xuanwu Hospital, Beijing | Completed | No outcome recorded |
| Phase 3 | NCT02086903 | Feb → Apr 2014 | — | Dong-A University | Completed | No outcome recorded |
| Phase 3 | NCT01961856 | Sep 2013 → Feb 2014 | — | University of Patras | Completed | No outcome recorded |
| Phase 3 | NCT01805596 | Apr 2013 → Feb 2016 | coronary artery disorder | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 3 | NCT01778842 | Mar → Jun 2013 | coronary artery disorder | Gennaro Sardella | Unknown | No outcome recorded |
| Phase 3 | NCT01812330 | Jan 2013 → Dec 2015 | acute coronary syndrome | General Hospital of Chinese Armed Police Forces | Unknown | No outcome recorded |
| Phase 3 | NCT02163954 | Jan → Aug 2013 | chronic kidney disease | Kyunghee University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01543932 | Jul 2012 → Dec 2013 | coronary artery disorder | University of Roma La Sapienza | Completed | No outcome recorded |
| Phase 3 | NCT01505790 | Jul 2011 → May 2012 | acute coronary syndrome | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 3 | NCT01598337 | Apr 2011 → Dec 2013 | coronary artery disorder | Prince Sultan Cardiac Center, Adult Cardiology Department. | Unknown | No outcome recorded |
| Phase 3 | NCT00944333 | Jul 2009 → Jun 2014 | intermediate coronary syndrome, ischemic disease | Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS | Terminated | No outcome recorded |
| Phase 3 | NCT00889044 | Apr 2009 → Dec 2010 | platelet aggregation, spontaneous | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00862420 | Feb 2009 → May 2011 | peripheral arterial disease | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00833703 | Jan 2009 → Jul 2010 | congenital heart disease | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00821834 | Dec 2008 → Aug 2010 | coronary artery disorder, myocardial infarction | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01046942 | Nov 2008 → May 2014 | thrombophilia, thrombotic disease | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase 3 | NCT00822666 | Oct 2008 → Dec 2009 | coronary artery disorder | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01032668 | Sep 2008 → Jul 2009 | coronary artery disorder | Bursa Postgraduate Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00638326 | Mar 2008 → Sep 2009 | coronary artery disorder | University of Pecs | Terminated | No outcome recorded |
| Phase 3 | NCT00776477 | Dec 2007 → Dec 2008 | atherosclerosis | China National Center for Cardiovascular Diseases | Unknown | No outcome recorded |
| Phase 3 | NCT00396877 | Nov 2006 → Feb 2010 | congenital heart disease | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00330772 | Jul 2006 → Jun 2008 | coronary artery disorder | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00335452 | Jun 2006 → Sep 2009 | acute coronary syndrome, intermediate coronary syndrome | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00305162 | Apr 2006 → May 2009 | acute coronary syndrome, myocardial infarction | The Medicines Company | Terminated | No outcome recorded |
| Phase 3 | NCT00444132 | Mar 2005 → Jun 2007 | — | Sheba Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00174759 | Sep 2004 → ? | arterial occlusion | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00693069 | Sep 2004 → Apr 2006 | coronary artery disorder | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Completed | No outcome recorded |
| Phase 3 | NCT00325390 | Jul 2004 → ? | acute coronary syndrome, platelet aggregation, spontaneous | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00716924 | May 2004 → Feb 2006 | thrombotic disease | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00243178 | Jul 2003 → Sep 2005 | atrial fibrillation, vascular disorder | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT00249873 | Jun 2003 → Mar 2009 | atrial fibrillation, vascular disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00714961 | Feb 2003 → Jan 2005 | acute coronary syndrome | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03289520 | Jan 2003 → Jun 2007 | kidney failure | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 3 | NCT00050817 | Oct 2002 → Aug 2005 | arteriosclerosis disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00235248 | Feb 2002 → Dec 2010 | brain infarction, transient ischemic attack | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4139 trials | ||||||
| Phase 4 | NCT07602257 | Jun 2026 → Dec 2029 expected | — | Ottawa Heart Institute Research Corporation | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07644234 | Jun 2026 → Dec 2028 expected | transient ischemic attack | Sichuan Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07592507 | May 2026 → Feb 2032 expected | coronary artery disorder | Daejeon St. Mary's hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06650488 | Jan 2026 → Jan 2030 expected | infective endocarditis, staphylococcus aureus infection | Todd C. Lee MD MPH FIDSA | Recruiting | No outcome recorded |
| Phase 4 | NCT07237308 | Dec 2025 → Jul 2029 expected | atrial fibrillation, intracranial arteriosclerosis, ischemic disease, stroke disorder | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07025148 | Oct 2025 → Aug 2027 expected | coronary artery disorder | University of Florida | Recruiting | No outcome recorded |
| Phase 4 | NCT07111559 | Aug 2025 → Mar 2028 expected | brain small vessel disease 4, ischemic stroke | Nippon Medical School | Recruiting | No outcome recorded |
| Phase 4 | NCT06588595 | Nov 2024 → Aug 2026 overdue | coronary artery disorder | University of Florida | Recruiting | No outcome recorded |
| Phase 4 | NCT06613191 | Oct 2024 → Dec 2025 overdue | coronary artery disorder, peripheral vascular disease | Ochsner Health System | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06402747 | Apr 2024 → Dec 2026 expected | atherosclerosis, type 2 diabetes mellitus | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| Show all 139 trials opens the full record — a long page | ||||||
| Phase not applicable44 trials | ||||||
| — | NCT07587099 | May 2026 → Dec 2029 expected | coronary artery disorder | Gan Lijun | Recruiting | No outcome recorded |
| — | NCT07432516 | Feb 2026 → Jun 2033 expected | coronary artery disorder | Yonsei University | Not yet recruiting | No outcome recorded |
| — | NCT06535568 | Jan 2026 → Jan 2028 expected | acute coronary syndrome, arterial occlusion, atherosclerosis, coronary stenosis | Fondazione Ricerca e Innovazione Cardiovascolare ETS | Recruiting | No outcome recorded |
| — | NCT06714526 | Oct 2025 → Aug 2027 expected | cerebral atherosclerosis | Sunnybrook Health Sciences Centre | Recruiting | No outcome recorded |
| — | NCT07198529 | Sep 2025 → Sep 2029 expected | coronary artery disorder | Korea University Guro Hospital | Recruiting | No outcome recorded |
| — | NCT07613840 | Apr 2025 → Apr 2027 expected | peripheral arterial disease, thrombotic disease | Massachusetts General Hospital | Recruiting | No outcome recorded |
| — | NCT06866665 | Mar 2025 → Dec 2030 expected | atrial fibrillation, coronary artery disorder | Yonsei University | Not yet recruiting | No outcome recorded |
| — | NCT06276374 | Jul 2024 → Nov 2029 expected | carotid artery disorder | Woo-Keun Seo | Recruiting | No outcome recorded |
| — | NCT06424548 | May 2024 → Jun 2028 expected | atherosclerosis, ischemic stroke | Ewha Womans University Seoul Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06175377 | Mar 2024 → Mar 2027 expected | arterial occlusion | Assistance Publique Hopitaux De Marseille | Not yet recruiting | No outcome recorded |
| — | NCT05761704 | Nov 2023 → Nov 2024 | atrial fibrillation | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT06058130 | Sep 2023 → Oct 2025 | atrial fibrillation, carotid stenosis, intracranial arteriosclerosis, ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT06053021 | Sep 2023 → Oct 2025 | ischemic stroke, thrombocytopenia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT05825391 | May → Oct 2023 | brain aneurysm | Beijing Tiantan Hospital | Completed | No outcome recorded |
| — | NCT05493657 | Feb 2023 → Jul 2026 overdue | aortic valve stenosis | Yonsei University | Recruiting | No outcome recorded |
| — | NCT07597239 | Dec 2022 → Feb 2026 overdue | arterial occlusion, peripheral arterial disease, thrombotic disease | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| — | NCT05623904 | Oct 2022 → Dec 2025 | carotid stenosis | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
| — | NCT05353140 | Sep 2022 → Sep 2028 expected | atrial fibrillation | Xijing Hospital | Recruiting | No outcome recorded |
| — | NCT05320926 | Jul 2022 → Jul 2028 expected | ischemic disease | Yonsei University | Recruiting | No outcome recorded |
| — | NCT04995159 | Sep 2021 → Jan 2026 overdue | coronary artery disorder | Lepu Medical Technology (Beijing) Co., Ltd. | Not yet recruiting | No outcome recorded |
| — | NCT04948749 | Jul 2021 → Dec 2027 expected | intracranial arteriosclerosis, stroke disorder | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT04333407 | Apr 2020 → Nov 2021 | COVID-19 | Imperial College London | Terminated | No outcome recorded |
| — | NCT03266731 | Jan 2018 → Jan 2019 | ischemic stroke | Assiut University | Unknown | No outcome recorded |
| — | NCT03111420 | Jan 2017 → Jun 2018 | platelet disorder, undefined | Aggredyne, Inc. | Completed | No outcome recorded |
| — | NCT02696226 | Feb 2016 → Jul 2017 | aortic valve disorder | The Cleveland Clinic | Terminated | No outcome recorded |
| — | NCT02865824 | Jan 2016 → Dec 2018 | polyp of colon | Incheon St.Mary's Hospital | Unknown | No outcome recorded |
| — | NCT02244710 | Mar 2015 → Sep 2016 | acute coronary syndrome | Fundación Investigación Sanitaria en León | Completed | No outcome recorded |
| — | NCT02079194 | Mar 2014 → Jul 2018 | coronary artery disorder | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT01701453 | Aug 2012 → Nov 2017 | acute coronary syndrome | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT02707445 | Sep 2011 → Feb 2016 | myocardial ischemia | Korea University Anam Hospital | Completed | No outcome recorded |
| — | NCT01233167 | Aug 2011 → Dec 2012 | coronary artery disorder | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| — | NCT03759067 | Oct 2010 → Jan 2012 | intermediate coronary syndrome | Korea University Anam Hospital | Completed | No outcome recorded |
| — | NCT01341600 | Jul 2010 → May 2011 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT01264640 | Jul 2010 → Feb 2011 | — | University of Rostock | Unknown | No outcome recorded |
| — | NCT02384070 | Jan 2009 → Dec 2013 | coronary artery disorder | Odessa Heart Institute | Completed | No outcome recorded |
| — | NCT01212302 | Oct 2008 → Mar 2010 | coronary artery disorder | Ruhr University of Bochum | Completed | No outcome recorded |
| — | NCT00781573 | Sep 2008 → Mar 2014 | myocardial infarction | North Texas Veterans Healthcare System | Completed | No outcome recorded |
| — | NCT00620646 | Feb → Dec 2008 | — | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT00644657 | Mar 2007 → Sep 2008 | intermediate coronary syndrome | University of Oklahoma | Completed | No outcome recorded |
| — | NCT00418860 | Sep 2006 → Apr 2008 | coronary artery disorder | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT00302913 | Dec 2005 → Jun 2006 | coronary artery disorder | University Heart Center Freiburg - Bad Krozingen | Completed | No outcome recorded |
| — | NCT00494156 | Jul 2003 → Jul 2008 | arterial disorder | C. Clay Cothren, MD | Withdrawn | No outcome recorded |
| — | NCT00262275 | Jul 2002 → Jul 2004 | ischemic disease | Papworth Hospital NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT00004564 | — | hyperlipidemia, thrombotic disease | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT00839345 | — | coronary artery disorder | Charles University, Czech Republic | Temporarily not available | No outcome recorded |
Also used as a comparator or background therapy in 485 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00797056 Background | Apr 2008 → Apr 2012 | peripheral vascular disease | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 131 trials | ||||||
| Phase 1 | NCT07619885 Comparator | Jun → Oct 2026 expected | acute coronary syndrome, acute myocardial infarction, peripheral arterial disease, stroke disorder | Shanghai CureGene Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07067775 Comparator | Aug 2025 | acute coronary syndrome | Jiangsu vcare pharmaceutical technology co., LTD | Completed | No outcome recorded |
| Phase 1 | NCT04091074 Comparator | Jan → Dec 2022 | carotid stenosis | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT04945616 Background | Jul → Oct 2021 | thrombotic disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04671069 Background | Jul → Aug 2019 | — | Madrigal Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03942458 Comparator | Apr → Jun 2019 | — | Jiangsu vcare pharmaceutical technology co., LTD | Completed | No outcome recorded |
| Phase 1 | NCT03078257 Background | Jan 2016 → Nov 2017 | coronary artery disorder | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 1 | NCT02439190 Comparator | Sep 2015 → Mar 2016 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02209350 Comparator | Aug 2015 → Nov 2020 | — | Meshalkin Research Institute of Pathology of Circulation | Completed | No outcome recorded |
| Phase 1 | NCT02419820 Background | Mar 2015 → Apr 2016 | acute coronary syndrome | IlDong Pharmaceutical Co Ltd | Terminated | No outcome recorded |
| Phase 1 | NCT02034292 Background | Feb → Mar 2014 | acute coronary syndrome | IlDong Pharmaceutical Co Ltd | Terminated | No outcome recorded |
| Phase 1 | NCT01744288 Comparator | Dec 2012 → Apr 2014 | platelet aggregation, spontaneous | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01860105 Comparator | Sep 2012 → Jan 2013 | — | The Medicines Company | Completed | No outcome recorded |
| Phase 1 | NCT01657071 Comparator | Mar → Apr 2012 | acute coronary syndrome | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01456546 Comparator | Oct 2011 → Jul 2013 | — | University of Southern Denmark | Completed | No outcome recorded |
| Phase 1 | NCT01526122 Comparator | Sep → Dec 2011 | atherosclerosis | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01496261 Comparator | Aug → Sep 2011 | coronary artery disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01422109 Comparator | Jul → Nov 2011 | acute coronary syndrome | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01388660 Comparator | Jun 2011 → Sep 2014 | coronary artery disorder | Ajou University School of Medicine | Unknown | No outcome recorded |
| Phase 1 | NCT01663038 Comparator | Dec 2010 → Jan 2011 | coronary artery disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01107925 Comparator | Mar 2010 → Aug 2011 | coronary artery disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01107912 Comparator | Mar 2010 → Oct 2011 | coronary artery disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01012219 Background | Nov 2009 → Mar 2010 | hyperlipidemia, combined, 2, hyperlipoproteinemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01107899 Comparator | Oct 2009 → Dec 2010 | acute coronary syndrome | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT00935506 Background | Jul → Oct 2009 | cardiovascular disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00732290 Comparator | Feb → May 2009 | — | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 1 | NCT00853450 Comparator | Feb → Jul 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01421706 Comparator | Jul 2008 → Jul 2009 | — | Inje University | Completed | No outcome recorded |
| Phase 1 | NCT01561950 Background | May 2008 → Jan 2009 | vascular hemostatic disease | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 1 | NCT00620802 Comparator | Nov 2007 → May 2008 | — | Cogentus Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00650169 Comparator | Dec 2004 → Jan 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03533153 Background | Mar 2021 → Dec 2023 | myocardial infarction | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 1/2 | NCT04434365 Background | Jun → Nov 2019 | coronary artery disorder | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03787927 Background | Dec 2018 → Dec 2021 | blood platelet disease, hemorrhagic disease, platelet disorder, undefined | Bloodworks | Unknown | No outcome recorded |
| Phase 234 trials | ||||||
| Phase 2 | NCT07032389 Background | Dec 2025 → Jun 2030 expected | acute coronary syndrome | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06601127 Comparator | Feb 2025 → Apr 2026 overdue | ischemic stroke | Tianjin Institute of Pharmaceutical Research Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT05233124 Background | Sep 2021 → Jun 2023 | acute coronary syndrome, vascular ectasia | Instituto Nacional de Cardiologia Ignacio Chavez | Unknown | No outcome recorded |
| Phase 2 | NCT04219774 Comparator | May 2020 → Mar 2024 | carotid artery occlusion, cognitive disorder, stroke disorder | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT04368377 Background | Apr 2020 | COVID-19, respiratory failure, thrombotic disease, viral pneumonia | University of Milan | Completed | No outcome recorded |
| Phase 2 | NCT03766581 Background | Jan 2019 → Mar 2022 | transient ischemic attack | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT03599284 Comparator | Aug 2018 → Jun 2019 | coronary atherosclerosis | Jiangsu vcare pharmaceutical technology co., LTD | Completed | No outcome recorded |
| Phase 2 | NCT03039205 Comparator | Nov 2017 → Dec 2019 | coronary artery disorder, impaired renal function disease, platelet aggregation, spontaneous | University of Sao Paulo | Completed | No outcome recorded |
| Phase 2 | NCT02677545 Comparator | Dec 2016 → Apr 2022 | carotid stenosis | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 2 | NCT02925923 Comparator | Nov 2016 → Jan 2018 | acute coronary syndrome, intermediate coronary syndrome | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT02578706 Comparator | Oct 2015 → Nov 2016 | HIV infectious disease | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT02519608 Comparator | Sep 2015 → Jun 2016 | chronic obstructive pulmonary disease, coronary artery disorder | University Hospital of Ferrara | Completed | No outcome recorded |
| Phase 2 | NCT02319941 Comparator | May 2015 → Feb 2017 | acute coronary syndrome | CardioVascular Research Foundation | Completed | No outcome recorded |
| Phase 2 | NCT02293395 Background | Apr 2015 → Oct 2016 | acute coronary syndrome | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02559414 Comparator | Feb 2015 → Apr 2016 | HIV infectious disease, cardiovascular disorder | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT02260622 Comparator | Oct 2014 → Jun 2017 | limb ischemia | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT01802775 Comparator | Feb 2013 → Dec 2014 | peripheral arterial disease | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT01455935 Comparator | Nov 2011 → Dec 2013 | stroke disorder | Jacobs Neurological Institute | Unknown | No outcome recorded |
| Phase 2 | NCT01235351 Comparator | Oct 2010 → Sep 2011 | myocardial infarction | The TIMI Study Group | Completed | No outcome recorded |
| Phase 2 | NCT02120092 Comparator | Oct 2010 → Dec 2013 | acute coronary syndrome | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2 | NCT01118325 Comparator | Apr 2010 → Mar 2011 | coronary artery disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01097343 Comparator | Mar 2010 → Apr 2011 | — | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT00910299 Comparator | Jul 2009 → Apr 2011 | coronary artery disorder | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2 | NCT00914368 Comparator | Jan 2009 → Mar 2010 | acute coronary syndrome, coronary artery disorder, myocardial infarction | Uppsala University | Completed | No outcome recorded |
| Phase 2 | NCT00751231 Comparator | Dec 2008 → Apr 2010 | — | Portola Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00642811 Comparator | May 2008 → Mar 2009 | coronary artery disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00642174 Comparator | Apr 2008 → Jan 2009 | coronary artery disorder, diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00528411 Comparator | Oct 2007 → Mar 2009 | coronary artery disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00385944 Comparator | Mar → Oct 2007 | acute coronary syndrome | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00684203 Background | Dec 2006 → Oct 2007 | atherosclerosis, myocardial infarction, myocardial ischemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00228423 Comparator | May 2006 → Jun 2009 | atherosclerosis | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00300339 Background | Feb 2006 → Dec 2007 | intermittent vascular claudication | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00368238 Background | Oct 2005 → Jul 2006 | — | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00059215 Comparator | Apr 2003 → Jan 2004 | heart disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/319 trials | ||||||
| Phase 2/3 | NCT06872541 Comparator | Jan 2025 → Oct 2026 expected | platelet aggregation, spontaneous | University of Sao Paulo | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT06238115 Background | Mar 2024 → Oct 2025 | intracranial berry aneurysm, thrombotic disease | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT05700266 Comparator | Dec 2023 → Dec 2024 | intracranial arteriosclerosis, ischemic stroke | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05565976 Background | Aug 2020 → Dec 2024 | cognitive impairment with or without cerebellar ataxia, ischemic stroke, metabolic syndrome X, vascular dementia | Jaime Daniel Mondragon | Unknown | No outcome recorded |
| Phase 2/3 | NCT03381742 Comparator | Dec 2017 → Dec 2018 | coronary artery disorder | First Affiliated Hospital of Harbin Medical University | Completed | No outcome recorded |
| Phase 2/3 | NCT03273322 Comparator | Sep 2017 → Nov 2018 | atrial fibrillation, hemorrhagic disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2/3 | NCT03062462 Comparator | Feb 2017 → Jul 2019 | coronary artery disorder | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02976701 Background | Nov 2016 → Jan 2023 | ST-elevation myocardial infarction | Dexa Medica Group | Terminated | No outcome recorded |
| Phase 2/3 | NCT02889549 Comparator | Aug 2016 → Oct 2017 | coronary artery disorder | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02506140 Comparator | Aug 2015 → Mar 2017 | transient ischemic attack | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02230527 Comparator | Oct 2014 → May 2020 | peripheral arterial disease | The Cleveland Clinic | Terminated | No outcome recorded |
| Phase 2/3 | NCT01924325 Comparator | Jan 2014 → Dec 2015 | transient ischemic attack | Xijing Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT01635426 Comparator | Mar 2012 → Jan 2018 | pregnancy loss, recurrent, 4 | Ain Shams University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01231165 Comparator | Feb 2009 → May 2010 | coronary artery disorder | University of Carabobo | Completed | No outcome recorded |
| Phase 2/3 | NCT00827346 Comparator | Jan 2009 → Apr 2011 | qualitative platelet defect | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 2/3 | NCT00816166 Comparator | Oct 2008 → Apr 2013 | transient ischemic attack | Codman & Shurtleff | Terminated | No outcome recorded |
| Phase 2/3 | NCT01586975 Comparator | Jul 2007 → Apr 2010 | ischemic stroke, myocardial infarction | Northwestern University | Completed | No outcome recorded |
| Phase 2/3 | NCT00163267 Comparator | Sep 2005 → Dec 2009 | peripheral arterial disease | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 2/3 | NCT00121446 Background | Jul 2003 → ? | myocardial infarction | University of Alberta | Completed | No outcome recorded |
| Phase 3104 trials | ||||||
| Phase 3 | NCT07572747 Comparator | Apr 2027 → Apr 2032 expected | coronary artery disorder | Khalid F Alhabib | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07379190 Background | Jun 2026 → Feb 2029 expected | cerebral infarction | Weifang Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT07468448 Comparator | May 2026 → Dec 2029 expected | cerebral atherosclerosis, ischemic stroke | Population Health Research Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07582835 Comparator | Apr 2026 → Apr 2028 expected | acute coronary syndrome, coronary artery disorder | Cardiocentro Ticino | Recruiting | No outcome recorded |
| Phase 3 | NCT07454707 Background | Apr 2026 → Dec 2031 expected | ischemic stroke | Sunnybrook Health Sciences Centre | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07347626 Comparator | Mar 2026 → Sep 2029 expected | ischemic stroke | Xinqiao Hospital of Chongqing | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07476898 Comparator | Mar 2026 → Jul 2028 expected | stroke disorder | First Hospital of China Medical University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07275749 Comparator | Dec 2025 → Jul 2026 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT07047014 Comparator | Jul 2025 → Mar 2027 expected | ischemic stroke, vascular occlusion disorder | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06414499 Comparator | Jul 2025 → Jul 2026 overdue | cerebrovascular disorder | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06954155 Comparator | May 2025 → Feb 2027 expected | ischemic stroke | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06577519 Comparator | Sep 2024 → Dec 2026 expected | acute coronary syndrome | Jiangsu vcare pharmaceutical technology co., LTD | Recruiting | No outcome recorded |
| Phase 3 | NCT06591338 Comparator | Sep 2024 → Sep 2025 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06082063 Comparator | Jul 2024 → Jul 2029 expected | heart failure, kidney failure, type 1 diabetes mellitus | Steno Diabetes Center Copenhagen | Recruiting | No outcome recorded |
| Phase 3 | NCT06360120 Comparator | Apr 2024 → Sep 2025 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06358313 Comparator | Apr 2024 → May 2026 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06318481 Comparator | Feb 2024 → Feb 2025 | ST-elevation myocardial infarction | National Institute of Cardiovascular Diseases, Pakistan | Completed | No outcome recorded |
| Phase 3 | NCT06037889 Comparator | Nov 2023 → Feb 2026 | cerebral atherosclerosis | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05627375 Comparator | Aug 2023 → Dec 2027 expected | venous thromboembolism | University Hospital of Saint-Etienne | Recruiting | No outcome recorded |
| Phase 3 | NCT05718531 Comparator | Feb 2023 → Feb 2025 | vascular ectasia | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT06242145 Comparator | Jan 2023 → Jul 2024 | ischemic stroke | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 3 | NCT05507645 Comparator | Nov 2022 → Mar 2024 | ischemic stroke, thrombotic disease | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05553613 Comparator | Oct 2022 → Oct 2023 | ischemic stroke | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 3 | NCT05047172 Comparator | Aug 2022 → Jan 2027 expected | intracranial arteriosclerosis, stroke disorder | University of Florida | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06242132 Comparator | Jun 2022 → Jul 2024 | ischemic stroke | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 3 | NCT06591351 Comparator | May 2022 → Sep 2024 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06591312 Comparator | May 2022 → Sep 2024 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06591299 Comparator | Apr 2022 → Sep 2024 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT05141305 Comparator | Jan 2022 → Jan 2024 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05077683 Background | Oct 2021 → Mar 2023 | acute myocardial infarction, thrombotic disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT06120725 Comparator | Sep 2021 → Sep 2023 | ischemic stroke | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 3 | NCT04946734 Background | Aug 2021 → Sep 2025 overdue | migraine disorder, patent foramen ovale | Guangdong Provincial People's Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04738097 Comparator | Aug 2021 → Oct 2023 | transient ischemic attack | Mazandaran University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT04770012 Comparator | Jun 2021 → Mar 2027 expected | — | Ottawa Heart Institute Research Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT05554822 Comparator | Jun 2021 → Dec 2023 | — | Azienda Ospedaliero Universitaria Maggiore della Carita | Unknown | No outcome recorded |
| Phase 3 | NCT04420351 Background | Oct 2020 → Feb 2023 | stroke disorder | The First Affiliated Hospital of Zhengzhou University | Completed | No outcome recorded |
| Phase 3 | NCT04229264 Comparator | Jan 2020 → Feb 2022 | limb ischemia | Science Valley Research Institute | Unknown | No outcome recorded |
| Phase 3 | NCT04045665 Background | Dec 2019 → Aug 2026 overdue | atrial fibrillation, hemorrhagic disease, stroke disorder | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 3 | NCT03961334 Comparator | Dec 2019 → Jan 2025 | ischemic stroke | University of Zurich | Unknown | No outcome recorded |
| Phase 3 | NCT04078737 Comparator | Sep 2019 → Jun 2021 | transient ischemic attack | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04069234 Comparator | Sep 2019 → Oct 2021 | coronary microvascular disorder, type 2 diabetes mellitus | Region Skane | Withdrawn | No outcome recorded |
| Phase 3 | NCT03649711 Comparator | Nov 2018 → Sep 2021 | chronic kidney disease, ischemic stroke, myocardial infarction | University of Arkansas | Completed | No outcome recorded |
| Phase 3 | NCT03078465 Comparator | Jun 2017 → May 2021 | coronary artery disorder | Nanjing First Hospital, Nanjing Medical University | Withdrawn | No outcome recorded |
| Phase 3 | NCT02866175 Background | Feb 2017 → Jun 2019 | atrial fibrillation | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 3 | NCT02617290 Comparator | Jan 2017 → May 2020 | coronary artery disorder, myocardial infarction, myocardial ischemia | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT02989558 Comparator | Dec 2016 → Feb 2020 | aortic valve stenosis | University of Athens | Completed | No outcome recorded |
| Phase 3 | NCT02960126 Comparator | Nov 2016 → Oct 2020 | atrial fibrillation | Chuncheon Sacred Heart Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02817789 Comparator | May 2016 → May 2018 | aortic valve stenosis | University Hospital, Bordeaux | Terminated | No outcome recorded |
| Phase 3 | NCT02833948 Comparator | May 2016 → Dec 2018 | aortic valve stenosis, cardiac valvular defect, thrombotic disease | ECRI bv | Completed | No outcome recorded |
| Phase 3 | NCT02689037 Background | Apr 2016 → Dec 2018 | cerebral atherosclerosis | The 476th Hospital of People's Liberation Army | Unknown | No outcome recorded |
| Phase 3 | NCT02556203 Comparator | Dec 2015 → Nov 2018 | — | Bayer | Terminated | No outcome recorded |
| Phase 3 | NCT02675205 Comparator | Dec 2015 → Jul 2020 | brain aneurysm | Fondation Ophtalmologique Adolphe de Rothschild | Completed | No outcome recorded |
| Phase 3 | NCT02429271 Comparator | Aug 2015 → Feb 2019 | ST-elevation myocardial infarction | Hellenic Cardiovascular Research Society | Completed | No outcome recorded |
| Phase 3 | NCT02298088 Comparator | Aug 2015 → Dec 2017 | ST-elevation myocardial infarction | Hospital do Coracao | Completed | No outcome recorded |
| Phase 3 | NCT02398656 Background | Apr 2015 → Jan 2024 | ischemic stroke | University of Calgary | Completed | No outcome recorded |
| Phase 3 | NCT02415803 Comparator | Dec 2014 → Dec 2016 | acute coronary syndrome | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT01774838 Comparator | Oct 2014 → Jun 2015 | acute coronary syndrome, intermediate coronary syndrome | University of Cologne | Completed | No outcome recorded |
| Phase 3 | NCT02164864 Background | Jul 2014 → Jun 2017 | atrial fibrillation | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02133989 Comparator | Jun 2014 → Dec 2017 | carotid stenosis | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT01930591 Comparator | May 2014 → Oct 2016 | acute myocardial infarction | Unity Health Toronto | Completed | No outcome recorded |
| Phase 3 | NCT01641510 Comparator | Oct 2013 → Oct 2018 | acute coronary syndrome | Dong-A University | Completed | No outcome recorded |
| Phase 3 | NCT01813435 Comparator | Jul 2013 → Nov 2015 | coronary artery disorder | ECRI bv | Completed | No outcome recorded |
| Phase 3 | NCT01758614 Comparator | Jun 2013 → Mar 2018 | carotid artery occlusion, cerebral artery occlusion, stroke disorder | Xuanwu Hospital, Beijing | Completed | No outcome recorded |
| Phase 3 | NCT01830543 Background | May 2013 → Jul 2016 | atrial fibrillation | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01757262 Comparator | Jan → Apr 2013 | coronary artery disorder | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 3 | NCT01732822 Comparator | Dec 2012 → Sep 2016 | peripheral arterial disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01609647 Comparator | Sep 2012 → Dec 2014 | acute coronary syndrome | Dong-A University | Completed | No outcome recorded |
| Phase 3 | NCT01790997 Comparator | May 2012 → Nov 2013 | ischemic stroke | Dexa Medica Group | Completed | No outcome recorded |
| Phase 3 | NCT01626534 Comparator | Mar 2012 → Feb 2014 | acute coronary syndrome | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 3 | NCT02070159 Comparator | Dec 2011 → Dec 2012 | coronary artery disorder | Dong-A University | Completed | No outcome recorded |
| Phase 3 | NCT01465828 Comparator | Oct 2011 → Jan 2012 | acute coronary syndrome | Gennaro Sardella | Completed | No outcome recorded |
| Phase 3 | NCT01515345 Comparator | Jul 2011 → Jan 2013 | coronary artery disorder, platelet aggregation, spontaneous | Kaiser Franz Josef Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01327534 Comparator | May 2011 → Mar 2013 | ST-elevation myocardial infarction | Stiftung Institut fuer Herzinfarktforschung | Completed | No outcome recorded |
| Phase 3 | NCT01338909 Comparator | Apr → Sep 2011 | myocardial infarction | University of Patras | Completed | No outcome recorded |
| Phase 3 | NCT01304472 Comparator | Feb → Apr 2011 | coronary artery disorder | University of Patras | Completed | No outcome recorded |
| Phase 3 | NCT01294462 Comparator | Feb 2011 → Jul 2012 | acute coronary syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01156571 Comparator | Sep 2010 → Dec 2012 | acute coronary syndrome, atherosclerosis | The Medicines Company | Completed | No outcome recorded |
| Phase 3 | NCT00991029 Comparator | May 2010 → Apr 2018 | transient ischemic attack | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 3 | NCT01155765 Comparator | May → Jul 2010 | chronic renal failure syndrome | University of Patras | Completed | No outcome recorded |
| Phase 3 | NCT01109784 Comparator | Apr → Jul 2010 | acute coronary syndrome, coronary artery disorder | University of Patras | Completed | No outcome recorded |
| Phase 3 | NCT00979589 Comparator | Dec 2009 → Mar 2012 | transient ischemic attack | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01510327 Background | Oct 2009 → Feb 2010 | coronary artery disorder | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02394145 Comparator | Sep 2009 → Aug 2015 | chronic kidney disease | Kyunghee University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00891670 Comparator | May → Jun 2009 | coronary stenosis, platelet aggregation, spontaneous | Gyeongsang National University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02294643 Comparator | Apr 2009 → Mar 2012 | chronic kidney disease, coronary artery disorder, diabetes mellitus | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01661322 Comparator | Apr 2009 → Sep 2017 | ischemic stroke | University of Nottingham | Terminated | No outcome recorded |
| Phase 3 | NCT00830960 Comparator | Feb 2009 → Jun 2010 | acute coronary syndrome | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01500434 Background | Feb 2009 → Mar 2011 | coronary artery disorder | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00823212 Background | Jan 2009 → Sep 2010 | coronary atherosclerosis | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00774475 Comparator | Nov 2008 → Nov 2010 | intermediate coronary syndrome, myocardial infarction | University of Florence | Unknown | No outcome recorded |
| Phase 3 | NCT00775762 Comparator | Nov 2008 → Jan 2009 | vascular disorder | Catholic University of the Sacred Heart | Unknown | No outcome recorded |
| Phase 3 | NCT00751491 Comparator | Sep 2008 → Sep 2009 | coronary artery disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 3 | NCT00697021 Comparator | Jun 2008 → Jun 2009 | ST-elevation myocardial infarction | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00699998 Comparator | Jun 2008 → Apr 2012 | acute coronary syndrome | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00623623 Background | Mar 2008 → Sep 2012 | myocardial infarction | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00557921 Background | Dec 2007 → Nov 2009 | acute coronary syndrome, coronary artery disorder, myocardial infarction | Cogentus Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00372216 Comparator | Oct 2006 → Oct 2009 | acute myocardial infarction | Stiftung Institut fuer Herzinfarktforschung | Completed | No outcome recorded |
| Phase 3 | NCT00391872 Comparator | Oct 2006 → Mar 2009 | acute coronary syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00385138 Background | Sep 2006 → May 2009 | acute coronary syndrome, atherosclerosis | The Medicines Company | Terminated | No outcome recorded |
| Phase 3 | NCT00432120 Comparator | Mar 2006 → Jul 2007 | ischemic disease | Charles University, Czech Republic | Completed | No outcome recorded |
| Phase 3 | NCT00238667 Comparator | Nov 2005 → May 2014 | carotid artery dissection, stroke disorder, vertebral artery dissection | St George's, University of London | Completed | No outcome recorded |
| Phase 3 | NCT00097591 Comparator | Nov 2004 → Jul 2007 | acute coronary syndrome, coronary atherosclerosis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00059306 Comparator | Feb 2003 → Apr 2012 | hypertensive disorder, stroke disorder | University of British Columbia | Completed | No outcome recorded |
| Phase 3 | NCT00007683 Comparator | Oct 1998 → Jul 2003 | heart failure | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 4229 trials | ||||||
| Phase 4 | NCT07683923 Comparator | Mar 2027 → Feb 2033 expected | acute coronary syndrome, idiopathic spontaneous coronary artery dissection | University Medical Center Hamburg-Eppendorf | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07609654 Comparator | Jun 2026 → Jun 2029 expected | atrial fibrillation, intracerebral hemorrhage, ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07511257 Background | Feb 2026 → Jun 2029 expected | ST-elevation myocardial infarction, acute coronary syndrome, vascular ectasia | Instituto Nacional de Cardiologia Ignacio Chavez | Recruiting | No outcome recorded |
| Phase 4 | NCT07080684 Comparator | Dec 2025 → Dec 2026 expected | coronary artery disorder | University of Messina | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07076082 Comparator | Oct 2025 → Oct 2027 expected | peripheral arterial disease | Corewell Health West | Recruiting | No outcome recorded |
| Show all 229 trials opens the full record — a long page | ||||||
| Phase not applicable64 trials | ||||||
| — | NCT07699003 Background | Aug 2026 → Aug 2029 expected | cerebral artery occlusion | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| — | NCT07583784 Comparator | Jul 2026 → Dec 2031 expected | ST-elevation myocardial infarction, atrial fibrillation | Chonnam National University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05650411 Comparator | Apr 2026 → May 2028 expected | coronary stenosis | IGLESIAS Juan Fernando | Recruiting | No outcome recorded |
| — | NCT07495969 Background | Apr 2026 → Dec 2027 expected | cerebral artery occlusion, ischemic stroke | Feng Gao | Not yet recruiting | No outcome recorded |
| — | NCT07169513 Comparator | Oct 2025 → Jul 2026 overdue | atherosclerosis, peripheral arterial disease | Guy's and St Thomas' NHS Foundation Trust | Not yet recruiting | No outcome recorded |
| — | NCT07089862 Comparator | Aug 2025 → Dec 2026 expected | brain aneurysm | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT06943586 Comparator | Apr 2025 → Apr 2028 expected | transient ischemic attack | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| — | NCT06899399 Comparator | Oct 2024 → Jul 2028 expected | internal carotid artery stenosis | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT05980195 Background | Jul 2024 → Dec 2025 overdue | carotid stenosis, cognitive impairment with or without cerebellar ataxia | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06015477 Comparator | Jan 2024 → Jul 2025 | brain aneurysm | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT06588231 Background | Oct 2023 → Dec 2024 overdue | coronary artery disorder | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| — | NCT05885932 Comparator | Aug 2023 → Sep 2025 overdue | ischemic stroke, precerebral artery stenosis | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| — | NCT05936606 Comparator | Aug 2023 → May 2027 expected | coronary artery disorder | Yonsei University | Recruiting | No outcome recorded |
| — | NCT05974033 Background | Aug 2023 → Dec 2025 overdue | intracranial arteriosclerosis | Changhai Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05960721 Comparator | Jul 2023 → Jul 2025 overdue | atrial fibrillation | Xijing Hospital | Recruiting | No outcome recorded |
| — | NCT05902000 Background | Jun 2023 → Jun 2025 | occlusion precerebral artery, stroke disorder | Xueli Cai | Unknown | No outcome recorded |
| — | NCT05744804 Comparator | Mar → Dec 2023 | myocardial infarction | Sohag University | Unknown | No outcome recorded |
| — | NCT05858918 Comparator | Oct 2022 → Mar 2023 | intermediate coronary syndrome | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| — | NCT05622500 Background | Sep 2022 → Apr 2025 | chronic venous insufficiency, post-thrombotic syndrome | Imperial College London | Terminated | No outcome recorded |
| — | NCT05770674 Comparator | Apr 2022 → Dec 2023 | coronary artery disorder | Kiyuk Chang | Unknown | No outcome recorded |
| — | NCT05209412 Background | Feb 2022 → Feb 2024 | coronary stenosis | Xijing Hospital | Unknown | No outcome recorded |
| — | NCT04989257 Comparator | Aug 2021 → Jun 2026 | ischemic disease | Yonsei University | Unknown | No outcome recorded |
| — | NCT06449469 Comparator | May 2021 → Apr 2026 overdue | aortic valve stenosis | Rigshospitalet, Denmark | Active not recruiting | No outcome recorded |
| — | NCT04581759 Background | Apr 2021 → Apr 2023 | ischemic stroke | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT04708587 Comparator | Mar 2021 → Mar 2027 expected | chronic kidney disease | Yonsei University | Recruiting | No outcome recorded |
| — | NCT04100135 Background | Feb 2021 → Aug 2024 | migraine disorder, patent foramen ovale | W.L.Gore & Associates | Terminated | No outcome recorded |
| — | NCT04744571 Background | Feb 2021 → Dec 2022 | arterial occlusion, coronary artery disorder | Beijing Anzhen Hospital | Unknown | No outcome recorded |
| — | NCT04261478 Comparator | Aug 2020 → Jun 2026 overdue | carotid stenosis, stroke disorder | University of Montreal Hospital Centre (CHUM) | Recruiting | No outcome recorded |
| — | NCT03896321 Comparator | Dec 2019 → Dec 2021 | coronary artery disorder | Assiut University | Completed | No outcome recorded |
| — | NCT04142151 Comparator | Sep 2019 → Dec 2020 | ischemic stroke | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| — | NCT04012541 Background | Jul 2019 → Mar 2021 | acute myocardial infarction, tooth disorder | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
| — | NCT05063630 Comparator | May 2019 → Oct 2021 | arterial occlusion, intracranial arterial disease, intracranial arteriosclerosis, ischemic stroke | Can Tho Stroke International Services Hospital | Unknown | No outcome recorded |
| — | NCT03703635 Background | Oct 2018 → May 2023 | cerebral artery stenosis | Ministry of Science and Technology of the People´s Republic of China | Unknown | No outcome recorded |
| — | NCT03447379 Background | Dec 2017 → Mar 2022 | coronary artery disorder | Gangnam Severance Hospital | Completed | No outcome recorded |
| — | NCT03204695 Background | May 2017 → Jun 2018 | atrial fibrillation | Coherex Medical | Terminated | No outcome recorded |
| — | NCT03102502 Background | Mar 2017 → Oct 2018 | coronary artery disorder | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT02843633 Background | Feb 2017 → Oct 2018 overdue | acute coronary syndrome | Biosensors Europe SA | Active not recruiting | No outcome recorded |
| — | NCT02975076 Comparator | Dec 2016 → Nov 2019 | transient ischemic attack | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| — | NCT02762864 Background | May 2016 → Apr 2019 | peripheral arterial disease | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| — | NCT02798874 Comparator | May → Dec 2016 | cardiovascular disorder | Chinese PLA General Hospital | Unknown | No outcome recorded |
| — | NCT02612480 Comparator | Oct → Dec 2015 | — | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT02331511 Comparator | Oct 2015 → May 2016 | conduction system disorder, vascular occlusion disorder | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT02618733 Comparator | Dec 2014 → Dec 2016 | acute coronary syndrome | Dong-A University | Completed | No outcome recorded |
| — | NCT02303717 Background | Dec 2014 → Dec 2017 | coronary artery disorder | NHS National Waiting Times Centre Board | Unknown | No outcome recorded |
| — | NCT02086019 Background | May 2014 → Sep 2019 | acute coronary syndrome | Brighton and Sussex University Hospitals NHS Trust | Completed | No outcome recorded |
| — | NCT02699008 Comparator | Jan 2014 → Aug 2015 | acute coronary syndrome | Wuhan Asia Heart Hospital | Completed | No outcome recorded |
| — | NCT02327741 Comparator | Oct 2012 → Sep 2014 | — | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| — | NCT01779401 Comparator | Sep 2012 → Sep 2016 | coronary artery disorder | Chinese Academy of Medical Sciences, Fuwai Hospital | Completed | No outcome recorded |
| — | NCT01665235 Background | Aug 2012 → Aug 2014 | cerebral artery stenosis | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT01482117 Comparator | Nov 2011 → Jan 2012 | — | Inje University | Completed | No outcome recorded |
| — | NCT01175200 Comparator | Sep 2010 → Jul 2012 | platelet aggregation, spontaneous | Ascopharm Groupe Novasco | Completed | No outcome recorded |
| — | NCT01103843 Comparator | Apr 2010 → Apr 2011 | coronary artery disorder | St. Francis Hospital, New York | Unknown | No outcome recorded |
| — | NCT01887704 Background | Jan 2010 → May 2013 | coronary artery disorder | Capital Medical University | Completed | No outcome recorded |
| — | NCT01037491 Comparator | Oct 2009 → Dec 2010 | duodenal ulcer, gastric ulcer | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| — | NCT01738542 Background | Apr 2009 → Nov 2010 | peripheral arterial disease | Hospital Universitario Getafe | Completed | No outcome recorded |
| — | NCT00738894 Background | Dec 2008 → Apr 2017 | transient ischemic attack | W.L.Gore & Associates | Completed | No outcome recorded |
| — | NCT00691314 Comparator | Jun 2008 → Sep 2010 | atherosclerosis, transient ischemic attack | Peking Union Medical College Hospital | Completed | No outcome recorded |
| — | NCT00645918 Comparator | Jun 2008 → Oct 2010 | acute coronary syndrome, coronary atherosclerosis | Accumetrics, Inc. | Completed | No outcome recorded |
| — | NCT00858715 Comparator | May 2008 → May 2012 | atherosclerosis | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT00619073 Comparator | Apr 2008 → May 2009 | blood platelet disease | University of Massachusetts, Worcester | Completed | No outcome recorded |
| — | NCT00664846 Background | Apr 2008 → Dec 2010 | ischemic stroke | Peking Union Medical College Hospital | Completed | No outcome recorded |
| — | NCT00662467 Comparator | Nov 2006 → Jan 2008 | myocardial infarction | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| — | NCT02800174 Comparator | Jun 2006 → Jun 2007 | carotid stenosis | Beijing Jishuitan Hospital | Completed | No outcome recorded |
| — | NCT00224809 Background | Sep 2002 → May 2007 | coronary artery disorder | Baylor Research Institute | Completed | No outcome recorded |
Press releases naming this drug 9 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-02-09 | Sanofi | New indication for Plavix® (clopidogrel) now approved in the European Union sanofi.com ↗ |
| 2008-08-25 | Daiichi Sankyo | Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events daiichisankyo.com ↗ |
| 2008-03-31 | Daiichi Sankyo | Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel daiichisankyo.com ↗ |
| 2008-03-05 | Bristol-Myers Squibb | New 300mg Loading Dose Tablet For Plavix® Receives Positive Opinion From The European Committee For Medicinal Products (CHMP) bms.com ↗ |
| 2007-11-04 | Daiichi Sankyo | Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel daiichisankyo.com ↗ |
| 2007-11-04 | Daiichi Sankyo | In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack daiichisankyo.com ↗ |
| 2007-03-01 | Daiichi Sankyo | Daiichi Pharmaceutical Concludes Joint Promotion of Plavix (R) with Sanofi-aventis daiichisankyo.com ↗ |
| 2007-01-18 | Daiichi Sankyo | Enrollment Completed in Pivotal Phase III Study Comparing Prasugrel to Clopidogrel in Patients with Acute Coronary Syndrome daiichisankyo.com ↗ |
| 2006-10-24 | Daiichi Sankyo | New Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses daiichisankyo.com ↗ |
Evidence & citations 29 cited values
Every value below carries the sentence it was read from. 812 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | clopidogrel | “Randomization will be stratified by stent type (cobalt-chromium everolimus-eluting stents, platinum-chromium everolimus-eluting stents, and sirolimus-eluting stents with...” PMID 29447787 ↗ Dec 2017801“evaluates the safety and efficacy of clopidogrel and aspirin as an alternative treatment in patients not eligible for recombinant tissue plasminogen activator or any other...” NCT03266731 ↗ “Aspirin 100mg once/day during the follow-up period, Clopidogrel 75mg once/day for at least 90 days, Atorvastatin 20-80mg once/day as the situation requires and risk factors...” NCT03703635 ↗ “The Investigator will decide if to use aspirin or clopidogrel, whereas ticagrelor or prasugrel are not recommended in our study population since no benefit (or even harm) has...” NCT06535568 ↗ “Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice...” NCT00823212 ↗ “Every antiplatelet-naïve patient undergoing an elective procedure will be given 300 mg aspirin and loading dose of one of P2Y12 receptor inhibitors (e.g., 600 mg clopidogrel,...” NCT02601157 ↗ “Five hundred patients with non-cardioembolic AIS presenting within 72 h of symptom onset will be randomized to receive either aspirin 100 mg and cilostazol 200 mg plus EGb 761...” PMID 39528058 ↗ Nov 2024 “Patients may be prescribed single antiplatelet therapy (e.g., aspirin or clopidogrel) or no antithrombotic therapy, strictly at the discretion of the treating physician based...” NCT07609654 ↗ “dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet...” NCT02762864 ↗ “All patients will receive antiplatelet treatment with the same dose of aspirin (100 mg o.d.) or ticlopidine (250 mg b.i.d) if intolerant ASA, or clopidogrel (75 mg o.d.), if...” NCT01208714 ↗ “Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on...” NCT03287167 ↗ “Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone after randomization at the discretion of site researchers according to Chinese Guidelines for Diagnosis...” NCT06954155 ↗ “Patients in the AT group will receive aspirin plus clopidogrel for 1 year, while patients in the ATW group receive aspirin plus clopidogrel for 1 year with extra warfarin...” PMID 41213699 ↗ Nov 2025 “One hundred patients showing high on-treatment residual ADP-inducible platelet reactivity in 2 or more tests will be randomized to receive either 75mg or 150mg of daily...” NCT00858715 ↗ “Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was...” NCT05623904 ↗ “Aggressive medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per...” NCT04948749 ↗ “Patients randomized to the antithrombotic monotherapy treatment receive any of the commercially available oral P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) and...” NCT05955365 ↗ “clopidogrel loading dose (if applicable), then dual antiplatelet therapy (placebo plus clopidogrel plus clinical ASA) for first 90 days, followed by placebo plus clinical ASA...” NCT07468448 ↗ “Subjects randomized 6 month DAPT will be prescribed either aspirin or thienopyridine (clopidogrel or ticlopidine) following 6 months DAPT for the duration of study, which is...” NCT01514227 ↗ “6 to 12 months of DAPT combining aspirin (≥75 mg od) and a P2Y12 inhibitor (clopidogrel 75 mg od, ticagrelor 90 mg bd, prasugrel 5 or 10 mg od at the discretion of the...” NCT05650411 ↗ “Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per...” NCT05980195 ↗ “Patients in the experimental group will be required to take indobufen (100 mg twice daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing...” NCT07089862 ↗ “Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months...” NCT02303717 ↗ “The subjects are randomized into study group and control group using central randomization for open-label dosing:(1) Study group: dabigatran etexilate 110 mg bid + aspirin 100...” NCT03536611 ↗ “The atorvastatin arm consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, an open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily...” NCT06358313 ↗ “Patients randomized to this arm will receive antiplatelet therapy throughout the study : aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then single antiplatelet therapy...” NCT05387954 ↗ “Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months...” NCT04708587 ↗ “Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with...” NCT01261832 ↗ “Current guidelines recommend dual antithrombotic therapy (DAT; OAC plus P2Y12 inhibitor - preferably clopidogrel) after a short course of triple antithrombotic therapy (TAT;...” PMID 39007830 ↗ Jul 2024 “Initiate dual antiplatelet therapy as early as possible (aspirin 100 mg/day plus clopidogrel 75 mg/day) for a total of 21 days, followed by long-term maintenance with aspirin...” NCT07379190 ↗ “Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first...” NCT04995159 ↗ “P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day)” NCT03447379 ↗ “Comparison of the Efficacy and Safety of Closone and Clopidogrel With Aspirin in Korean Patients With Coronary Artery Disease (a Single-center, Randomized, Open-label Clinical Trial)” NCT01763749 ↗ “Standard therapy which consists of: aspirin enteric-coated tablet 1 x 80 mg and clopidogrel film-coated tablet 1 x 75 mg daily for four weeks will be given to both arms.” NCT02976701 ↗ “Patients were randomized either to 1 to 2 months of DAPT followed by clopidogrel monotherapy (n = 2078) or to 12 months of DAPT with aspirin and clopidogrel (n = 2091).” PMID 35234821 ↗ Apr 2022 “Participants will receive intensive medical management, including aspirin (75-325 mg/day) or alternative antiplatelet agents (clopidogrel/dipyridamole) for intolerance.” NCT06899399 ↗ “dabigatran 110mg twice daily or 150mg twice daily+ aspirin 100mg once daily / clopidogrel 75mg once daily / ticagrelor 90mg twice daily / cilostazol 100mg twice daily” NCT06058130 ↗ “This group will be given medical treatment including aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter.” NCT05063630 ↗ “Antithrombotic agents include, but are not limited to: warfarin (titrated to international normalised ratio, INR), apixaban, rivaroxaban, aspirin, and clopidogrel.” NCT05622500 ↗ “All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.” NCT02402491 ↗ “Antiplatelet treatment: with aspirin 75mg OD is mandatory except for concomitant anticoagulant therapy or allergy. In case of allergy clopidogrel will be used.” NCT06082063 ↗ “Patients were randomized either to 1 month of DAPT followed by clopidogrel monotherapy (n=1523) or to 12 months of DAPT with aspirin and clopidogrel (n=1522).” PMID 31237644 ↗ Jun 2019 “The polypill will consist of a high-intensity statin (rosuvastatin 40 mg daily), aspirin 81 mg daily, and either clopidogrel 75 mg or prasugrel 10 mg daily.” NCT05514938 ↗ “The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.” NCT02800174 ↗ “The Investigator will decide whether to use ticagrelor first; if ticagrelor is not the first-line recommended drug, then clopidogrel will be considered.” NCT07587099 ↗ “Low dose aspirin (single agent) will be the choice of most physicians, some Investigators will chose to use the combination of aspirin and clopidogrel.” NCT02398656 ↗ “The polypill combines DAPT and a high intensity statin: (a) aspirin 81 mg, (b) rosuvastatin (40 or 10 mg) and (c) prasugrel 10 mg or clopidogrel 75 mg.” NCT07032389 ↗ “Subjects must be treated with one of the following P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor) for 3 months following the index procedure.” NCT02605447 ↗ “Anti-inflammatory: "TromboACC" (acetylsalicylate acid) up to 2 g per day and/or "Clopidogrel" (thienopyridine class antiplatelet agent) - 75mg per day.” NCT01700075 ↗ “Aspirin 100 mg orally once daily + Clopidogrel 75 mg orally once daily, or Aspirin 100 mg + Ticagrelor 90 mg orally twice daily, continued for 21 days” NCT07476898 ↗ “Aspirin 100 mg and Clopidogrel 75 mg daily for 1 month, followed by single antiplatelet therapy (Aspirin 100 mg or Clopidogrel 75 mg) up to 12 months.” NCT07592507 ↗ “clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure).” NCT01510327 ↗ “For the first day, clopidogrel with loading dose 300mg, and aspirin 100mg were given, and followed by clopidogrel 75 mg and aspirin 100mg each day” NCT03552354 ↗ “Doses are aspirin either 81mg or loading dose 325mg, clopidogrel either 75mg or loading dose 300mg, ticagrelor either 90mg or loading dose 180mg.” NCT06943586 ↗ “Patients receive aspirin and clopidogrel for 1 month after PCI. After 1 month, aspirin is discontinued and clopidogrel monotherapy is continued.” NCT07198529 ↗ “Aspirin 81 mg taken concomitantly with clopidogrel 75 mg as maintenance doses is standard of care in some patients with cardiovascular disease.” NCT01557335 ↗ “Clopidogrel is a blood thinner drug that acts on the platelet cell membrane. By this mechanism, clopidogrel inhibits the platelets aggregation.” NCT00989300 ↗ “Guideline- driven standard medical treatment including statins,antiplatelet drugs（aspirin or Clopidogrel ）, anti-ischemic drugs （Nitroglycerin）” NCT03102502 ↗ “Subjects who are thienopyridine naive will be randomized 1:1 to either clopidogrel 600 mg or prasugrel 60 mg loading dose at the time of PCI.” NCT01103843 ↗ “Dual antiplatelet therapy with aspirin plus clopidogrel will be given for the following period after PCI according to patient allocation” NCT05770674 ↗ “A second agent (usually Clopidogrel 300mg PO) is added after follow-up brain imaging at 12-24 hours confirms absence of significant ICH.” NCT04261478 ↗ “DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin.” NCT03606642 ↗ “A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders” NCT00642811 ↗ “antiplatelet (aspirin or/and clopidogrel,100-300mg/d) and lipid-lowering (atorvastatin 20-60mg/d,rosuvastatin 10-20mg/d) drugs” NCT04581759 ↗ “* Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily)” NCT01589978 ↗ “In the P2Y12 inhibitor group, ticagrelor was used in 372 participants (78.8%) and clopidogrel in 100 participants (21.2%).” PMID 37227729 ↗ May 2023 “Aspirin and clopidogrel (or other P2Y12 inhibitor) will be used and dosing is according to standard institutional practice” NCT02843633 ↗ “Clopidogrel is indicated as an alternative in case of aspirin intolerance (Class 2 of recommendation, Level C of evidence)” NCT05752916 ↗ “Aspirin Enteric-coated Tablets (Bay Aspirin) 100mg once a night+Clopidogrel Sulfate Tablets (Plavix) 75mg once daily.” NCT05902000 ↗ “The other group discontinued antiplatelets (i.e. clopidogrel, ticagrelor, prasugrel) for 7 days before colonoscopy.” NCT02865824 ↗ “aspirin 100 mg daily plus clopidogrel 75 mg daily or ticagrelor 90 mg per dose, twice daily for 30 consecutive days” NCT07195812 ↗ “Prasugrel (10 mg/day) or Ticagrelor (180 mg/day) are strongly recommended as compared to Clopidogrel (75 mg/day)).” NCT02118870 ↗ “with aspirin and a thienopyridine (clopidogrel or ticlopidine\]) beyond that described in the product labeling.” NCT00963781 ↗ “Medical therapy alone: received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after randomisation.” NCT05974033 ↗ “medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg” NCT01763320 ↗ “P2Y12 receptor inhibitor (i.e. Clopidogrel, 300 or 600mg loading dose orally, followed by 75 mg orally daily)” NCT05122780 ↗ “Aspirin 100 mg and clopidogrel 300 mg are administered within 6 ± 2 hours following thrombolytic therapy” NCT06414499 ↗ “Group 2: Aspirin 80-100 mg/day + clopidogrelª 75 mg/day followed by aspirin 80-100 mg/day for 9 months#” NCT05632445 ↗ “Patients will be conventionally received ticagrelor 90mg bid or clopidogrel 75mg qd + aspirin 100 mg qd” NCT06283888 ↗ “All eligible STEMI patients will be received standard DAPT (ticagrelor or clopidogrel plus aspirin).” NCT06013020 ↗ “75 mg clopidogrel per day (or ticagrelor or cilostazol) for the initial 90 days after randomization” NCT07495969 ↗ “Then, only the same oral P2Y12 inhibitor (clopidogrel, prasugrel, and ticagrelor) up to 12 months.” NCT05952206 ↗ “patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.” NCT01502943 ↗ “A loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg” NCT02698618 ↗ “Clopidogrel (Plavix) Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.” NCT01339026 ↗ “CGT 2168 (clopidogrel, 75 mg and omeprazole, 20 mg) relative to Plavix® (clopidogrel, 75 mg)” NCT00620802 ↗ “non-carriers and patients in the standard treatment group were given 75 mg clopidogrel daily” PMID 22464343 ↗ Mar 2012 “Plavix®/Iscover® from Sanofi-Aventis as the original formulation of clopidogrel-bisulphate.” NCT01147133 ↗ “clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months” NCT03284827 ↗ “Antiplatelet therapy with aspirin (100 mg) and/or clopidogrel (75 mg) will be administered” NCT07347626 ↗ “dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion” NCT05567562 ↗ “Clopidogrel 75mg + Aspirin 100mg 1 month, after 1 month, change to aspirin 100mg 1 year.” NCT06015477 ↗ “One sachet of aspirin 160 mg and one tablet of clopidogrel 75 mg per day.during 3 months” NCT04796714 ↗ “Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone are being used.” NCT05141305 ↗ “aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)” NCT05077683 ↗ “Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d” NCT00166257 ↗ “clopidogrel 75 mg/d in case of allergy or gastrointestinal intolerance to aspirin” NCT02539810 ↗ “acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months” NCT02798913 ↗ “dual antiplatelet (aspirin 100 mg + clopidogrel 75 mg daily) for first 90 days” NCT07699003 ↗ “Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)” NCT04045665 ↗ “but aspirin 100mg once daily or clopidogrel 75mg once daily was recommended.” NCT03718559 ↗ “* Month 1-12: Aspirin 100 mg qd + Clopidogrel 75 mg qd (Switched at 1 month)” NCT07432516 ↗ “doses of clopidogrel (n = 94), prasugrel (n = 43) or ticagrelor, (n = 143).” PMID 34143384 ↗ Jun 2021 “Single APT with either aspirin or clopidogrel is discontinued in this arm.” NCT01962545 ↗ “100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month” NCT01267734 ↗ “Aspirin (at a daily dose ≤100 mg) or Clopidogrel (at a daily dose ≤75mg)” NCT05627375 ↗ “Aspirin + Clopidogrel are required from 46 days to 12 months after LAAO.” NCT05353140 ↗ “Aspirin + clopidogrel for 3-months schedule after the coronary stenting” NCT02609698 ↗ “Drug: Aspirin 100mg and clopidogrel 75mg Duration of treatment:24 weeks” NCT04135677 ↗ “clopidogrel (loading dose of 300mg before maintenance dose of 75 mg/d)” NCT03533153 ↗ “Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone” NCT07047014 ↗ “Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)” NCT01069003 ↗ “Dual antiplatelet therapy with aspirin 200mg and clopidogrel 300mg.” NCT07111559 ↗ “antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day)” NCT00691314 ↗ “1-month prasugrel monotherapy followed by clopidogrel monotherapy” NCT04609111 ↗ “Aspirin 100mg qd; Clopidogrel 75mg qd (after first dose of 300mg)” NCT07095790 ↗ “Patients with aspirin resistance were given clopidogrel 75mg qd” NCT06269432 ↗ “* Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month” NCT01354808 ↗ “Clopidogrel 75 mg (Plavix 75mg) plus Aspirin (juspirin) 81 mg.” NCT04168398 ↗ “A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin” NCT01388660 ↗ “Patient will receive dual anti platelet asprin And clopidogrel” NCT03896321 ↗ “aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol” NCT03062319 ↗ “Antiplatelet: aspirin 100 mg/day + clopidogrel 75 mg/day.” NCT07088523 ↗ “Aspirin 100 mg + clopidogrel 75 mg for 4 weeks post-LAAC” NCT05761704 ↗ “aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2)” NCT03415386 ↗ “late de-escalation (clopidogrel monotherapy >6 months)” PMID 40886179 ↗ May 2026 “Aspirin and clopidogrel 30 days after DES implantation” NCT06339021 ↗ “Free choice among clopidogrel, prasugrel or ticagrelor” NCT01477775 ↗ “Preloading with Aspirin and Clopidogrel before TAVI” NCT03001960 ↗ “with accompanied aspirin and clopidogrel treatment” NCT01163604 ↗ “Ticagrelor (180 mg/day) or Clopidogrel (75 mg/day)” NCT03008083 ↗ “Day 1：clopidogrel 300mg/day+ aspirin100-300mg/ day” NCT03635749 ↗ “Aspirin, clopidogrel or other antiplatelet drugs.” NCT04491695 ↗ “immediate clopidogrel at 300 mg loading regimen” NCT00929279 ↗ “Apixaban and clopidogrel combination therapy” NCT06866665 ↗ “Clopidogrel: administered 75 mg once per day” NCT02735707 ↗ “50 patients treated with clopidogrel 75mg” NCT05903976 ↗ “ADP-MPA\<20%, give clopidogrel 37.5mg qd.” NCT05825391 ↗ “Including aspirin and clopidogrel, etc.” NCT03179618 ↗ “Aspirin 75 mg qd + Clopidogrel 75 mg qd” NCT03273322 ↗ “Including aspirin and clopidogrel, etc.” NCT03179514 ↗ “clopidogrel 75 mg q.d. (Sanofi, France)” NCT03234114 ↗ “Including aspirin and clopidogrel, etc.” NCT03171597 ↗ “Including aspirin and clopidogrel, etc” NCT03179527 ↗ “Clopidogrel ± other antiplatelet drug” NCT05995600 ↗ “Aspirin, clopidogrel, anticoagulant” NCT05507645 ↗ “conventional clopidogrel (Plavix®)” NCT01349777 ↗ “Clopidogrel 75 mg +Aspirin 161 mg” NCT04393025 ↗ “AAS 100mg/d or Clopidogrel 75mg/d” NCT01738542 ↗ “aspirin 100mg or clopidogrel 75mg” NCT03073850 ↗ “aspirin, clopidogrel, ticagrelor” NCT04012541 ↗ “stroke (aspirin, clopidogrel)” NCT02670161 ↗ “DAPT with clopidogrel and ASA” NCT05262803 ↗ “Clopidogrel 75mg twice daily” NCT04619927 ↗ “Clopidogrel plus Aspirin arm” NCT04014803 ↗ “Clopidogrel 75mg PO q24h” NCT05565976 ↗ “clopidogrel can be used” NCT04950790 ↗ “Aspirin and Clopidogrel” NCT03056118 ↗ “clopidogrel 75 mg daily” NCT01500434 ↗ “Clopidogrel Bisulfate” NCT05574374 ↗ “Clopidogrel (Plavix)” NCT01475552 ↗ “Drug: Clopidogrel” NCT04695106 ↗ “clopidogrel,” NCT02086019 ↗ “clopidogrel” NCT01349777 ↗ “Clopidogrel” NCT01339026 ↗ “Clopidogrel” NCT07572747 ↗ “Clopidogrel” NCT00738894 ↗ “clopidogrel” NCT02198300 ↗ |
| Known as | A brand name for clopidogrel is PLAVIX. | “A brand name for clopidogrel is PLAVIX.” NCT01510327 ↗ |
| Known as | acetysalicylic acid | “acetysalicylic acid” NCT02198300 ↗ |
| Known as | Blinded clopidogrel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01121224 ↗ |
| Known as | CLO | “Clopidogrel (CLO) is a pro-drug metabolized in the liver by the Cytochrom-P450 system to its active component.” NCT03385538 ↗ |
| Known as | Clop. | “A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders” NCT00642811 ↗ |
| Known as | Clopidogrel (Plavix) | “Clopidogrel (Plavix)” NCT01475552 ↗7“Clopidogrel (Plavix)” NCT02163954 ↗ “Clopidogrel (Plavix)” NCT00799045 ↗ “clopidogrel = PLAVIX” NCT01147133 ↗ “Clopidogrel (Plavix)” NCT03606642 ↗ “Clopidogrel (Plavix)” NCT02224274 ↗ “Clopidogrel: plavix” NCT00822536 ↗ “Clopidogrel: Plavix” NCT01663038 ↗ |
| Known as | clopidogrel 75mg tab | “clopidogrel 75mg tab” NCT05567562 ↗ |
| Known as | Clopidogrel = KARDOGREL | “Clopidogrel = KARDOGREL” NCT01493999 ↗ |
| Known as | Clopidogrel bisulfate | “A number of 352 patients scheduled for elective percutaneous coronary intervention (PCI) with a native coronary stenosis suitable for DES implantation and OCT imaging are...” NCT02140801 ↗6“Clopidogrel bisulfate, a potent antiplatelet agent, has a pivotal role in the prevention and treatment of atherothrombotic disease.” PMID 23328268 ↗ Jan 2013 “plavix : Clopidogrel bisulfate (Sanofi-Aventis) 75mg” NCT00947843 ↗ “clopidogrel bisulfate 97.875mg(75mg as clopidogrel)” NCT02133989 ↗ “Mylan's clopidogrel bisulfate 75 mg tablets” NCT00650169 ↗ “Clopidogrel Bisulfate Tablets 75 mg” NCT00648947 ↗ “Drug: Clopidogrel bisulfate” NCT01447563 ↗ |
| Known as | clopidogrel napadisilate | “Clopidogrel napadisilate, a different salt preparation of clopidogrel, has been developed and approved in Korea and several European countries.” PMID 23328268 ↗ Jan 2013 |
| Known as | Clopidogrel resinate | “Pregrel: Clopidogrel resinate (CKD Pharmaceutical) 75mg” NCT00947843 ↗ |
| Known as | clopidogrel-bisulphate | “Plavix®/Iscover® from Sanofi-Aventis as the original formulation of clopidogrel-bisulphate.” NCT01147133 ↗ |
| Known as | COPIGREL | “COPIGREL® - clopidogrel dosed at 75 mg per tablet” NCT03329261 ↗ |
| Known as | Iscover | “Clopidogrel (Plavix® and/or Iscover®) is an agent inhibiting platelet aggregation involved in clot formation.” NCT00050817 ↗1“Plavix®/Iscover® from Sanofi-Aventis as the original formulation of clopidogrel-bisulphate.” NCT01147133 ↗ |
| Known as | Kardogrel | “generic clopidogrel = Kardogrel” NCT01147133 ↗ |
| Known as | Piece clopidogrel | “patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.” NCT01502943 ↗ |
| Known as | Plavitor | “generic clopidogrel (Plavitor® )” NCT02060786 ↗ |
| Known as | Plavix | “Clopidogrel (Plavix) is currently a widely used thienopyridine that has been used for the treatment of patients presenting with the acute coronary syndrome and patients...” NCT00827346 ↗36“One group took acetylsalicylic acid (ASA) 80 mg once daily and clopidogrel 75 mg that is produced by Sanofi company available in market as Plavix once a day” NCT05858918 ↗ “Following a baseline punch biopsy, all subjects will then receive oral clopidogrel (Plavix®) over a period of approximately 3 to 4 days.” NCT01603342 ↗ “Participants that are not carriers of the CYP2C19 gene will receive either Plavix monotherapy or dual therapy with Plavix and Aspirin.” NCT07602257 ↗ “Aspirin Enteric-coated Tablets (Bay Aspirin) 100mg once a night+Clopidogrel Sulfate Tablets (Plavix) 75mg once daily.” NCT05902000 ↗ “Clopidogrel (Plavix® and/or Iscover®) is an agent inhibiting platelet aggregation involved in clot formation.” NCT00050817 ↗ “Patiënt interventional treatment, with dabigatran + clopidogrel (plavix) 75mg once daily up to 12 months.” NCT04688723 ↗ “versus co-administration of Plavix (clopidogrel) and Astrix (aspirin) in healthy male volunteers.” NCT01657071 ↗ “Clopidogrel (Plavix) Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.” NCT01339026 ↗ “Aspirin and Clopidogrel (Plavix) for 1-month post-procedure followed by Aspirin indefinitely.” NCT07076082 ↗ “Clopidogrel (Plavix) 75 mg qd, 2 weeks; followed with Ticagrelor (Brilinta) 90 mg bd, 2 weeks” NCT02459288 ↗ “Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin)” NCT01388660 ↗ “Plavix®/Iscover® from Sanofi-Aventis as the original formulation of clopidogrel-bisulphate.” NCT01147133 ↗ “Clopidogrel (Plavix®) (Bristol Myers Squibb/Sanofi Pharmaceuticals, Princeton, NJ, USA)” PMID 23826440 ↗ Jun 2013 “Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.” NCT03471169 ↗ “Clopidogrel 75 mg (Plavix 75mg) plus Aspirin (juspirin) 81 mg.” NCT04168398 ↗ “clopidogrel (Plavix) 600mg (8 tablets) one time” NCT00732290 ↗ “plavix is a original brand name of clopidogrel” NCT00947843 ↗ “Plavix (clopidogrel) and Astrix (aspirin)” NCT01422109 ↗ “relative to Plavix® (clopidogrel, 75 mg)” NCT00620802 ↗ “clopidogrel (the brand name is Plavix)” NCT02260622 ↗ “Plavix (clopidogrel 75 mg) and aspirin” NCT00557921 ↗ “ASA (aspirin), Clopidogrel (Plavix)” NCT01212302 ↗ “conventional clopidogrel (Plavix®)” NCT01349777 ↗ “original clopidogrel (Plavix® )” NCT02060786 ↗ “Clopidogrel (Plavix®) tablet” NCT01557335 ↗ “2. Plavix 75 mg PO daily or” NCT01455935 ↗ “Plavix (Clopidogrel)” NCT00589862 ↗ “Clopidogrel (Plavix)” NCT00648453 ↗ “Clopidogrel (Plavix)” NCT01475552 ↗ “Clopidogrel: Plavix” NCT01496261 ↗ |
| Known as | PLAVIX (clopidogrel) | “PLAVIX (clopidogrel)” NCT01589978 ↗ |
| Known as | plavix : Clopidogrel bisulfate (Sanofi-Aventis) 75mg | “plavix : Clopidogrel bisulfate (Sanofi-Aventis) 75mg” NCT00947843 ↗ |
| Known as | pregrel | “pregrel is a generic brand name of clopidogrel” NCT00947843 ↗ |
| Known as | Pregrel: Clopidogrel resinate (CKD Pharmaceutical) 75mg | “Pregrel: Clopidogrel resinate (CKD Pharmaceutical) 75mg” NCT00947843 ↗ |
| Known as | SR25990 | “Drug: Clopidogrel (SR25990)” NCT00396877 ↗5“clopidogrel (SR25990)” NCT00862420 ↗ “clopidogrel (SR25990)” NCT00821834 ↗ “clopidogrel (SR25990)” NCT00050817 ↗ “Clopidogrel (SR25990)” NCT00115375 ↗ “Clopidogrel (SR25990)” NCT00714961 ↗ |
| Known as | SR25990C | “clopidogrel (SR25990C)” NCT00243178 ↗ |
| Action | Inhibit | “(an antiplatelet agent whose mechanism is ADP inhibition) administered in a double blind manner)” NCT00007683 ↗ |
| Modality | Small molecule | “clopidogrel, a thienopyridine inhibitor of the platelet P2Y12 adenosine diphosphate (ADP) receptor” NCT01012193 ↗ |
| Route | Oral | “Clopidogrel is an oral antiplatelet agent that has been shown to prevent strokes and heart attacks.” NCT00004564 ↗ |
| Target | P2RY12 | “they act by inhibiting the the P2Y12 ADP receptor on platelets.” NCT00611286 ↗ |